Pfizer Inc PFE
Pfizer Inc (NYSE: PFE) is a drug developer. Its lead program, Marketed portfolio (Eliquis, Vyndaqel family, Padcev, Lorbrena and others), is in Phase 3.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Padcev (enfortumab vedotin) | Muscle-invasive bladder cancer, bladder sparing (additional use of marketed product) | antibody | Phase 3 |
| PF-07872412 | Pneumococcal disease, pediatrics | vaccine | Phase 3 |
| Sigvotatug vedotin | Previously treated non-squamous NSCLC (Phase 3 SigVie-002 missed overall survival endpoint, June 2026) | antibody | Phase 3 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.